Kiora Pharmaceuticals Inc
Nasdaq · Healthcare · Pharmaceutical Preparations · Encinitas, CA
KPRX chart
What traders are saying about $KPRX
Latest postsKiora Pharmaceuticals Inc news
- Kiora Pharmaceuticals, Inc. Estimates – NASDAQ:KPRX
TradingView ·
- Kiora Pharmaceuticals (KPRX) Slips 0.43% to $2.34 as Shares Test Lower End of Recent Range - Charm Flow
https://www.siam.in/ ·
- Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Yahoo Finance ·
- Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Yahoo Finance ·
- Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance ·
- SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer
Yahoo Finance ·
- SS Innovations names Sarah Romano as CFO
medtechdive.com ·
- Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Yahoo Finance ·
- Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Yahoo Finance ·
- Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance ·
- Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Yahoo Finance ·
- Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
Yahoo Finance ·
Kiora Pharmaceuticals Inc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | – |
| Net income | -$10,835 | $3,595 | -$12,514 | -$13.6M |
| Diluted EPS | $-2.64 | $0.87 | $-24.25 | $-18.55 |
| Total assets (year end) | $24.3M | $36.5M | $13.7M | $18.7M |
| Cash and equivalents (year end) | $8.7M | $3.8M | $2.5M | $6.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Kiora Pharmaceuticals Inc
- Ticker
- KPRX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Encinitas, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1372514
- Former names
- EYEGATE PHARMACEUTICALS INC
Frequently asked questions
What exchange is Kiora Pharmaceuticals Inc listed on?
Kiora Pharmaceuticals Inc trades on the Nasdaq under the ticker symbol KPRX.
What industry is Kiora Pharmaceuticals Inc in?
Kiora Pharmaceuticals Inc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Kiora Pharmaceuticals Inc headquartered?
Kiora Pharmaceuticals Inc's business address on file with the SEC is in Encinitas, CA.
When does Kiora Pharmaceuticals Inc's fiscal year end?
Kiora Pharmaceuticals Inc's fiscal year ends on December 31.
How much revenue did Kiora Pharmaceuticals Inc report?
Kiora Pharmaceuticals Inc reported $0 in revenue for calendar year 2025, according to its SEC filings.